TurtleTree debuts first-ever animal-free lactoferrin–one of milk’s most valuable and functional proteins–in world-first tasting
Known affectionately as "pink gold," TurtleTree premiers its highly-prized, health-boosting, pink-hued protein—LF+—in an exclusive tasting before 2023 market entry. WOODLAND, Calif., March 16, 2023 /PRNewswire/ -- TurtleTree, a global leader in animal-free functional dairy proteins, will today debut the world's first precision fermentation-produced lactoferrin —LF+—a high-value bioactive milk protein and one of the most powerful parts of cow's milk,...
Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals
Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism Hospital Programme, announcing the four (4) shortlisted finalists for the programme, namely National Heart Institute (Institut Jantung Negara),...
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib （ABSK021）was granted BTD by FDA and CDE, discovered and developed by China biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbisko Therapeutics" hereafter) announced that the U.S. FDA had approved its CSF-1R...
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of antibody and anti cancer activity of cytotoxin. ADC shave developed rapidly as tumor therapeutics in recent years....
FDA Approves Expanded Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection...
Akeso Reported 2022 Annual Results
Strong sales fully demonstrated Akeso's commercialization ability: Products sales totaled RMB1,104.4 million, increasing 422% .开坦尼® (cadonilimab) recorded strong sales of RMB546.3 million in its first six months of approval in China. 安尼可®(penpulimab injection, PD-1) recorded product sales of RMB558.1 million, increasing 164%. Breakthrough overseas licensing: Exclusive development licensing rights were granted...
Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD
Ark Biopharmaceutical will lead development activities for AK0705 with the goal of initiating clinical studies in 2024. Calibr will continue to collaborate in the development of AK0705. The collaboration is an extension of the current co-development collaboration. SHANGHAI, March 16, 2023 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio), a global biopharmaceutical company focusing on discovery...
KPC LYFE Acquires Bikram Yoga
LOS ANGELES, March 16, 2023 /PRNewswire/ -- KPC Group is excited to announce the expansion of its healthcare offerings to include KPC LYFE. KPC LYFE, the KPC Group's holistic health initiative, has acquired the widely recognized and internationally famous Bikram Yoga. This acquisition of Bikram Yoga provides an unparalleled opportunity for the KPC Group to add this iconic brand,...
CStone Pharmaceuticals Reports 2022 Annual Results and Business Updates
The total revenue for 2022 was RMB 481.4 million, with commercial revenue of RMB 394.1 million, which represents a 142% increase compared to the previous year Healthy financial position with cash reserves of RMB 1.042 billion as of December 31, 2022. The net loss has decreased by 55% from the previous year Two new products successfully launched including...
Lunit to Present 5 Abstracts at the 2023 AACR Annual Meeting
Five posters from Lunit and collaborators demonstrate important progress in the development of novel diagnostics for important cancer therapies, including immunotherapy SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer solutions, today announced its participation in the American Association for Cancer Research...
